Compare D R Horton Inc (DHI) vs Halozyme Therapeutics Inc. Common Stock (HALO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
D R Horton Inc vs Halozyme Therapeutics Inc. Common Stock — how do they compare? D R Horton Inc trades at $134.46 (market cap $37.99B), while Halozyme Therapeutics Inc. Common Stock trades at $112.53 (market cap $12.58B). The key difference: D R Horton Inc is far larger — about 3× Halozyme Therapeutics Inc. Common Stock's market cap, and D R Horton Inc pays a 1.33% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold D R Horton Inc for 46 Days and Halozyme Therapeutics Inc. Common Stock for 1 Days on average.
| DHI | HALO | |
|---|---|---|
Market Cap | $37.99B | $12.58B |
Volume | 2,974,460 | 2,179,278 |
Sector | Consumer Cyclical | Health |
52-Week High | $167.78 | $115.22 |
52-Week Low | $132.53 | $61.63 |
Typical Hold Time | 46 Days | 1 Days |
Enterprise Value | $43.09B | $14.49B |
Dividend Yield | 1.33% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
D.R. Horton (DHI) trades at $134.49, down 0.91% on the day amid broader housing sector weakness. The stock shows bearish technical signals with resistance at $137 and support at $133. Fundamentally, the company maintains solid profitability with 9.15% net margin and 12.75% ROE, though revenue declined to $34.25B in 2025. Recent earnings beats and a $0.45 dividend declaration provide some positive catalysts despite macroeconomic headwinds affecting homebuilders.
DHI presents a mixed outlook with attractive valuation (P/E 12.95) and strong analyst support (47% buy ratings, $156.57 target) offset by housing market risks. Rising mortgage rates and inflation concerns create near-term pressure, but the company's consistent earnings performance and buyback capacity offer long-term value. Investors should weigh the discounted valuation against sector-specific macroeconomic challenges.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →
